Q3 Asset Management Takes $1.43 Million Position in Invesco Biotechnology & Genome ETF $PBE

Q3 Asset Management purchased a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 17,429 shares of the company’s stock, valued at approximately $1,431,000.

Other hedge funds also recently made changes to their positions in the company. United Capital Financial Advisors LLC bought a new stake in Invesco Biotechnology & Genome ETF during the third quarter valued at $5,946,000. Royal Bank of Canada boosted its stake in Invesco Biotechnology & Genome ETF by 22.3% during the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after buying an additional 13,767 shares during the period. Bank of America Corp DE boosted its stake in Invesco Biotechnology & Genome ETF by 2.5% during the third quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock valued at $4,186,000 after buying an additional 1,453 shares during the period. Goldman Sachs Group Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 5.9% during the first quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock valued at $2,389,000 after buying an additional 2,103 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 7.7% during the third quarter. Envestnet Asset Management Inc. now owns 19,723 shares of the company’s stock valued at $1,378,000 after buying an additional 1,408 shares during the period.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA:PBE opened at $81.87 on Monday. The firm has a market capitalization of $254.62 million, a price-to-earnings ratio of 20.44 and a beta of 0.76. Invesco Biotechnology & Genome ETF has a 52-week low of $58.15 and a 52-week high of $85.73. The stock has a fifty day moving average of $79.60 and a 200 day moving average of $79.31.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.